Quantifiable bradykinesia, gait abnormalities and Huntington's disease- like striatal lesions in rats chronically treated with 3-nitropropionic acid

Neuroscience

Volumn 79, Issue 1, 1997, Pages 45-56

  Guyot, M C ^a   Hantraye, P ^a   Dolan, R ^a   Palfi, S ^a   Maziere M ^a   Brouillet, E ^a  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

Author keywords

Motor behaviour; Neurodegenerative diseases; Neuronal counts; Quantitative video movement analysis; Rat model

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; BRADYKINESIA; ENERGY EXPENDITURE; GAIT DISORDER; HUNTINGTON CHOREA; MALE; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; STRIATE CORTEX;

ANALYSIS OF VARIANCE; ANIMALS; CORPUS STRIATUM; DIHYDROLIPOAMIDE DEHYDROGENASE; DRUG ADMINISTRATION SCHEDULE; GAIT; GLIAL FIBRILLARY ACIDIC PROTEIN; HAPLORHINI; HUNTINGTON DISEASE; MALE; MOTOR ACTIVITY; MOVEMENT DISORDERS; NEURONS; NEUROTOXINS; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES;

EID: 0030997707     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(96)00602-1     Document Type: Article

References (53)

1. Albin R. L. and Greenamyre J. T. (1992) Alternative excitotoxic hypotheses. Neurology 42, 733-738.
2. Beal M. F. (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31, 119-130.
3. Beal M. F., Brouillet E., Jenkins B. G., Ferrante R. J., Kowall N. W., Miller J. M., Storey E., Srivastava R., Rosen B. R. and Hyman B. T. (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13, 4181-4192.
4. Beal M. F., Brouillet E., Jenkins B. G., Henshaw R., Rosen B. and Hyman B. T. (1993) Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61, 1147-1150.
5. Beal M. F., Ferrante R. J., Swartz K. J. and Kowall N. W. (1991) Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11, 1649-1659.
6. Beal M., Kowall N., Ellison D., Swartz K., Mac Garvey U., Bird E. and Martin J. (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168-171.
7. Beal M. F., Swartz K. J., Hyman B. T., Storey E., Finn S. T. and Koroshetz W. (1991) Aminooxyacetic acid results in excitotoxin lesions by a novel indirect mechanism. J. Neurochem. 57, 1068-1073.
8. Borlongan C. V., Koutouzis T. X., Randall T. S., Freeman T. B., Cahill D. W. and Sanberg P. R. (1995) Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats. Brain Res. Bull. 36, 549-556.
9. Brouillet E., Guyot M. C., Dolan R., Mazière M. and Hantraye P. (1994) Hislological and behavioural effects of chronic 3-nitropropionic acid treatment in old rats. Soc. Neurosci. Abstr. 20, 1255.
10. Brouillet E., Hantraye P., Ferrante R. L., Dolan R. A. L.-W., Kowall N. W. and Beal M. F. (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. natn. Acad. Sci. U.S.A. 92, 7105-7109.
11. Brouillet E., Hyman B. T., Jenkins B. G., Henshaw D. R., Schulz J. B., Sodhi P., Rosen B. R. and Beal M. F. (1994) Systemic or local administration of azide produces striatal lesions by an energy impairment-induced excitotoxic mechanism. Expl Neurol. 129, 175-182.
12. Brouillet E., Jenkins B. G., Hyman B. T., Ferrante R. J., Kowall N. W., Srivastava R., Roy D. S., Rosen B. R. and Beal M. F. (1993) Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 60, 356-359.
13. Brouillet E. P., Shinobu L., McGarvey U., Hochberg F. and Beal M. F. (1993) Manganese injection into the rat striatum produces excitotoxic lesions by impairing energy metabolism. Expl Neurol. 120, 89-94.
14. Brown L. (1992) Somatotopic organization in rat striatum: evidence for a combinational map. Proc. natn. Acad. Sci. U.S.A. 89, 7403-7407.
15. Burke J. R., Enghild J. J., Martin M. E., Jou Y. S., Myers R. M., Roses A. D., Vance J. M. and Strittmatter W. J. (1996) Huntington and DRPLA proteins selectively intereact with the enzyme GAPDH. Nat. Med. 2, 347-350.
16. Coyle L. T. and Schwarcz R. (1976) Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263, 244-246.
17. Dolan R., McIntyre L., Brouillet E., Varastet M., Maziére M. and Hantraye P. (1993) Analysis of locomotor activity in non-human primate models of Parkinson's and Huntington's diseases. Soc. Neurosci. Abstr. 19, 403.
18. Ferrante R. J., Kowall N. W., Beal M. F., Richardson Jr E. P., Bird E. D. and Martin J. B. (1985) Selective sparing of a class of striatal neurons in Huntington's disease. Science 230, 561-563.
19. Ferrante R. J., Kowall N. W. and Richardson E. P. J. (1991) Proliferative and degenerative changes in striatal spiny-neurons in Huntington's disease: a combine study using the section-Golgi method and calbindin D28k immunochemistry. J. Neurosci. 11, 3877-3887.
20. Gould H., Wilson M. P. and Hamar D. W. (1985) Brain enzyme and clinical alterations induced in rats and mice by nitroaliphatic toxicants. Toxic. Lett. 27, 83-89.
21. Graveland G., Williams R. S. and DiFiglia M. (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227, 770-773.
22. Greene J. G., Porter R. H., Eller R. V. and Greenamyre J. T. (1993) Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J. Neurochem. 61, 1151-1154.
23. Hamilton B. F. and Gould D. H. G. (1987) Correlation of morphological brain lesions with physiological alterations and blood-brain barrier impairment by 3-nitropropionic acid toxicity in rats. Acta Neuropath. 74, 67-74.
24. Hantraye P., Riche D., Maziere M. and Isacson O. (1990) An experimental primate model of Huntington's disease: anatomical and behavioural studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Expl Neurol. 108, 91-104.
25. Hantraye P., Riche D., Maziere M. and Isacson O. (1992) Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington's disease. Proc. natn. Acad. Sci. U.S.A. 89, 4187-4191.
26. Harper P. S. (1991) Huntington's Disease, Vol. 1. W. B. Saunders, London.
27. Hedreen J. and Folstein S. (1995) Early loss of neostriosome neurons in Huntington's disease. J. Neuropath. exp. Neurol. 54, 105-120.
28. Illarioshkin S. N., Igarashi S., Onodera O., Markova E., Nikolskaya N., Tanaka H., Chabrashwili T., Insarova N., Endo K., Ivanova-Smolenskaya I. and Tsuji S. (1994) Trinucleotide repeat length and rate of progression of Huntington's disease. Ann. Neurol. 36, 630-635.
29. Kanazawa L., Kimura M., Mutrata M., Tanaka Y. and Cho F. (1986) Choreic movements induced by unilateral kainate lesions of the striatum and L-Dopa administration in monkey. Neurosci. Lett. 71, 241-246.
30. Koller W. C. and Trimble J. (1985) The gait abnormality of Huntington's disease. Neurology 35, 1450-1454.
31. Koutouzis T. K., Borlongan C. V., Freeman T. B., Cahill D. W. and Sanberg P. R. (1994) Intrastriatal 3-nitropropionic acid: a behavioral assessment. NeuroReport 5, 2241-2245.
32. Koutouzis T. K., Borlongan C. V., Scorcia T., Creese I., Cahill D. W., Freeman T. B. and Sanberg P. R. (1994) Systemic 3-nitropropionic acid: long-term effects on locomotor behavior. Brain Res. 646, 242-246.
33. Kowall N. W., Ferrante R. J. and Martin J. B. (1987) Patterns of cell loss in Huntington's disease. Trends Neurosci. 10, 24-29.
34. Kremer B., Weber B. and Hayden M. R. (1992) New insights into the clinical features, pathogenesis and molecular genetics of Huntington's disease. Brain Path. 2, 321-335.
35. Li S. H., Schilling G., Young W. S., Li X. J., Margolis R. L., Stine O. C., Wagster M. V., Abbot M. H., Franz M. L., Ranen N. G., Folstein S. E., Hedreen J. C. and Ross C. A. (1993) Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 11, 985-993.
36. Ludolph A. C., He F., Spencer P. S., Hammerstad J. and Sabri M. (1991) 3-Nitroproprionic acid - exogenous animal neurotoxin and possible human striatal toxin. Can. J. neurol. Sci. 18, 492-498.
37. Ludolph A. C., Seeling M., Ludolph A., Novitt P., Allen C. N. and Sabri M. I. (1992) 3-Nitropropionic acid decreases cellular energy levels and causes neurodegeneration in cortical explants. Neurodegeneration 1, 155-161.
38. McGeer E. G. and McGeer P. L. (1976) Duplication of biochemical changes of Huntington's chorea by intrastriatal injection of glutamic and kainic acids. Nature 263, 517-519.
39. Myers R. H., Vonsattel J. P., Stevens T. J., Cupples L. A., Richardson E. P., Martin J. B. and Bird E. D. (1988) Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology 38, 341-347.
40. Nishino H., Shimano Y., Kumazaki M. and Saurai T. (1995) Chronically administered 3-nitropropionic acid induces striatal lesions attributed to dysfunction of the blood-brain barrier. Neurosci. Lett. 186, 161-164.
41. Palfi S., Ferrante R. J., Brouillet E., Beal M. F., Dolan R., Guyot M. C., Peschanski M. and Hantraye P. (1996) Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J. Neurosci. 16, 3019-3025.
42. Palfi S., Guyot M. C., Hantraye P., Altairac S. and Brouillet E. (1996) Characterization of the inhibition of brain succinate dehydrogenase after systemic administration of 3-nitropropionic acid. Soc. Neurosci. Abstr. 22, 1905.
43. Riepe M., Ludolph A., Seeling M., Spencer P. S. and Ludolph A. C. (1994) Increase of ATP levels by glutamate antagonists is unrelated to neuroprotection. NeuroReport 5, 2130-2132.
44. Schulz J. B., Henshaw D. R., Jenkins B. G., Ferrante R. J., Kowall N. W., Rosen B. R. and Beal M. F. (1995) 3-Acetylpyridine produces age-dependent excitotoxic lesions in rat striatum. J. Cerebr. Blood Flow Metab. 14, 1024-1029.
45. Simpson J. R. and Isacson O. (1993) Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum. Expl Neurol. 121, 57-64.
46. Snell R. G., MacMillan J. C., Cheadle J. P., Fenton I., Lazarou L. P., Davies P., MacDonald M. E., Gusella J. F., Harper P. S. and Shaw D. J. (1993) Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 4, 393-397.
47. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome. Cell 72, 971-983.
48. Thomson P. D., Berardelli A., Rothwell J. C., Day B. L., Dick S. P. R., Beneeke R. and Marsden C. D. (1988) The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain 111, 223-244.
49. Turski L. and Ikonomidou H. (1994) Striatal toxicity of 3-nitropropionic acid prevented by the AMPA antagonist NBQX. Soc. Neurosci. Abstr. 20, 1677.
50. Vonsattel J. P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D. and Richardson E. P. (1985) Neuropathological classification of Huntington's disease. J. Neuropath. exp. Neurol. 44, 559-577.
51. Weller M. and Paul S. M. (1993) 3-Nitropropionic acid is an indirect excitotoxin to cultured cerebellar granule neurons. Eur. J. Pharmac. 248, 223-228.
52. Wullner U., Young A. B., Penney J. B. and Beal M. F. (1994) 3-Nitropropionic acid toxicity in the striatum. J. Neurochem. 63, 1772-1781.
53. Zeevalk G. D., Derr-Yellin E. and Nicklas W. J. (1995) NMDA receptor involvement in toxicity to dopamine neurons in vitro caused by the succinate dehydrogenase inhibitor 3-nitropropionic acid. J. Neurochem. 64, 455-458.